<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:00:08Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9471979" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9471979</identifier>
        <datestamp>2022-10-14</datestamp>
        <setSpec>jamasd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id>
              <journal-title-group>
                <journal-title>JAMA Network Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2574-3805</issn>
              <publisher>
                <publisher-name>American Medical Association</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9471979</article-id>
              <article-id pub-id-type="pmcid">PMC9471979</article-id>
              <article-id pub-id-type="pmc-uid">9471979</article-id>
              <article-id pub-id-type="pmid">36098968</article-id>
              <article-id pub-id-type="pmid">36098968</article-id>
              <article-id pub-id-type="doi">10.1001/jamanetworkopen.2022.31206</article-id>
              <article-id pub-id-type="publisher-id">zoi220884</article-id>
              <article-categories>
                <subj-group subj-group-type="category" specific-use="electronic">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Investigation</subject>
                </subj-group>
                <subj-group subj-group-type="online-only">
                  <subject>Online Only</subject>
                </subj-group>
                <subj-group subj-group-type="subject-area">
                  <subject>Geriatrics</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Effect of Vitamin D<sub>3</sub> and Omega-3 Fatty Acid Supplementation on Risk of Frailty</article-title>
                <subtitle>An Ancillary Study of a Randomized Clinical Trial</subtitle>
                <alt-title alt-title-type="headline">Effect of Vitamin D<sub>3</sub> and Omega-3 Fatty Acid Supplementation on Risk of Frailty</alt-title>
                <alt-title alt-title-type="running-head">Effect of Vitamin D<sub>3</sub> and Omega-3 Fatty Acid Supplementation on Risk of Frailty</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Orkaby</surname>
                    <given-names>Ariela R.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MPH</degrees>
                  <xref rid="zoi220884aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="zoi220884aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="zoi220884aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dushkes</surname>
                    <given-names>Rimma</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi220884aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ward</surname>
                    <given-names>Rachel</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi220884aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="zoi220884aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="zoi220884aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Djousse</surname>
                    <given-names>Luc</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>ScD</degrees>
                  <xref rid="zoi220884aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="zoi220884aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="zoi220884aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Buring</surname>
                    <given-names>Julie E.</given-names>
                  </name>
                  <degrees>ScD</degrees>
                  <xref rid="zoi220884aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="zoi220884aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="zoi220884aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lee</surname>
                    <given-names>I-Min</given-names>
                  </name>
                  <degrees>MBBS</degrees>
                  <degrees>ScD</degrees>
                  <xref rid="zoi220884aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="zoi220884aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="zoi220884aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cook</surname>
                    <given-names>Nancy R.</given-names>
                  </name>
                  <degrees>ScD</degrees>
                  <xref rid="zoi220884aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="zoi220884aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="zoi220884aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>LeBoff</surname>
                    <given-names>Meryl S.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi220884aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="zoi220884aff7" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                  <xref rid="zoi220884aff8" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Okereke</surname>
                    <given-names>Olivia I.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>SM</degrees>
                  <xref rid="zoi220884aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="zoi220884aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                  <xref rid="zoi220884aff9" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Copeland</surname>
                    <given-names>Trisha</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <degrees>RD</degrees>
                  <xref rid="zoi220884aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Manson</surname>
                    <given-names>JoAnn E.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>DrPH</degrees>
                  <xref rid="zoi220884aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="zoi220884aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="zoi220884aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="zoi220884aff1"><label>1</label>New England Geriatric Research, Education, and Clinical Center, Veterans Affairs Boston Healthcare System, Boston, Massachusetts</aff>
              <aff id="zoi220884aff2"><label>2</label>Division of Aging, Brigham and Women’s Hospital, Boston, Massachusetts</aff>
              <aff id="zoi220884aff3"><label>3</label>Harvard Medical School, Boston, Massachusetts</aff>
              <aff id="zoi220884aff4"><label>4</label>Division of Preventive Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts</aff>
              <aff id="zoi220884aff5"><label>5</label>Massachusetts Veterans Epidemiology Research and Information Center, Veterans Affairs Boston Healthcare System, Boston, Massachusetts</aff>
              <aff id="zoi220884aff6"><label>6</label>Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts</aff>
              <aff id="zoi220884aff7"><label>7</label>Endocrinology, Diabetes, and Hypertension Division, Brigham and Women’s Hospital, Boston, Massachusetts</aff>
              <aff id="zoi220884aff8"><label>8</label>Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts</aff>
              <aff id="zoi220884aff9"><label>9</label>Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts</aff>
              <author-notes>
                <title>Article Information</title>
                <p><bold>Accepted for Publication:</bold> July 18, 2022.</p>
                <p content-type="published-online"><bold>Published:</bold> September 13, 2022. <?xpp bx;1?>doi:<uri content-type="doi">10.1001/jamanetworkopen.2022.31206</uri></p>
                <p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. © 2022 Orkaby AR et al. <italic>JAMA Network Open</italic>.</p>
                <corresp id="zoi220884cor1"><bold>Corresponding Author:</bold> Ariela R. Orkaby, MD, MPH, Harvard Medical School, 150 S Huntington Ave, Boston, MA 02130 (<email xlink:href="aorkaby@bwh.harvard.edu">aorkaby@bwh.harvard.edu</email>).</corresp>
                <p content-type="author-contributions"><bold>Author Contributions</bold>: Dr Orkaby had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p>
                <p><italic>Concept and design:</italic> Orkaby, Manson.</p>
                <p><italic>Acquisition, analysis, or interpretation of data:</italic> All authors.</p>
                <p><italic>Drafting of the manuscript:</italic> Orkaby, Dushkes.</p>
                <p><italic>Critical revision of the manuscript for important intellectual content:</italic> Orkaby, Ward, Djousse, Buring, Lee, Cook, LeBoff, Okereke, Copeland, Manson.</p>
                <p><italic>Statistical analysis:</italic> Orkaby, Dushkes, Ward, Cook.</p>
                <p><italic>Obtained funding:</italic> Okereke, Manson.</p>
                <p><italic>Administrative, technical, or material support:</italic> Ward, Lee, LeBoff, Copeland, Manson.</p>
                <p><italic>Supervision:</italic> Djousse, Okereke, Copeland, Manson.</p>
                <p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Buring reported receiving grants from the National Institutes of Health (NIH) during the conduct of the study and that her spouse was a member of the Pharmavite Scientific Advisory Board when the trial began. Dr Lee reported receiving grants from the NIH during the conduct of the study. Dr Okereke reported receiving royalties from Springer Publishing for a book on late-life depression prevention outside the submitted work. Dr Manson reported receiving grants from the NIH during the conduct of the study and grants from the NIH and Mars Edge outside the submitted work. No other disclosures were reported.</p>
                <p content-type="funding-statement"><bold>Funding/Support:</bold> The Vitamin D and Omega-3 (VITAL) trial was supported by NIH grants U01 CA138962, R01 CA138962, and R01 AT011729, which included support from the National Cancer Institute, National Heart, Lung and Blood Institute, Office of Dietary Supplements, National Institute of Neurological Disorders and Stroke, and National Center for Complementary and Integrative Health. Dr Orkaby is supported by Veterans Affairs CSR&amp;D CDA-2 award IK2-CX001800, and Dr Okereke was supported by NIH grant R01 MH091448.</p>
                <p><bold>Role of the Funder/Sponsor:</bold> The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p>
                <p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZOI220884-1-s" ref-type="supplementary-material">Supplement 4</xref>.</p>
                <p><bold>Additional Contributions:</bold> Pharmavite LLC (vitamin D<sub>3</sub>) and Pronova BioPharma/BASF (omega-3 fatty acids) donated the study agents, matching placebos, and packaging. Quest Diagnostics performed the serum 25-hydroxyvitamin D and plasma phospholipid omega-3 measurements at no additional cost. We are grateful to the participants of the VITAL trial.</p>
              </author-notes>
              <pub-date pub-type="epub" iso-8601-date="2022-09-13T10:00">
                <day>13</day>
                <month>9</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>9</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>13</day>
                <month>9</month>
                <year>2022</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>5</volume>
              <issue>9</issue>
              <elocation-id>e2231206</elocation-id>
              <history>
                <date date-type="received">
                  <day>19</day>
                  <month>4</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>18</day>
                  <month>7</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright 2022 Orkaby AR et al. <italic>JAMA Network Open</italic>.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf-version" xlink:href="jamanetwopen-e2231206.pdf">jamanetwopen-e2231206.pdf</self-uri>
              <self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.31206"/>
              <related-article related-article-type="commentary" ext-link-type="doi" id="ZIC220185" xlink:href="10.1001/jamanetworkopen.2022.31147"/>
              <abstract abstract-type="key-points">
                <title>Key Points</title>
                <sec id="ab-zoi220884-1">
                  <title>Question</title>
                  <p>Does supplementation with vitamin D<sub>3</sub> and/or omega-3 fatty acids reduce the risk of frailty?</p>
                </sec>
                <sec id="ab-zoi220884-2">
                  <title>Findings</title>
                  <p>In this ancillary study of a randomized clinical trial including 25 871 individuals aged 50 years or older, neither vitamin D<sub>3</sub>, 2000 IU/d, nor omega-3 fatty acid, 1 g/d, supplementation, compared with placebo, significantly affected change in frailty score during 5 years of treatment. Results were unchanged using the frailty physical phenotype.</p>
                </sec>
                <sec id="ab-zoi220884-3">
                  <title>Meaning</title>
                  <p>The results of this ancillary study do not support the routine use of vitamin D<sub>3</sub> or omega-3 fatty acid supplementation in community-dwelling older adults for the prevention of frailty.</p>
                </sec>
              </abstract>
              <abstract>
                <sec id="ab-zoi220884-4">
                  <title>Importance</title>
                  <p>Preventive strategies for frailty are needed. Whether supplements with anti-inflammatory properties, such as vitamin D<sub>3</sub> or marine omega-3 fatty acids, are useful for frailty prevention is unknown.</p>
                </sec>
                <sec id="ab-zoi220884-5">
                  <title>Objective</title>
                  <p>To test the effects of vitamin D<sub>3</sub> and omega-3 supplements on change in frailty in older individuals.</p>
                </sec>
                <sec id="ab-zoi220884-6">
                  <title>Design, Setting, and Participants</title>
                  <p>This study was conducted in 2021, as a prespecified ancillary to the Vitamin D and Omega-3 (VITAL) trial, a 2 × 2 factorial randomized clinical trial. A total of 25 871 individuals (men aged ≥50 years and women aged ≥55 years), without cancer or cardiovascular disease and with data on frailty, were recruited across all 50 US states from November 2011 to March 2014 and followed up through December 31, 2017. Data analysis for the ancillary study was conducted from December 1, 2019, to March 30, 2022.</p>
                </sec>
                <sec id="ab-zoi220884-7">
                  <title>Interventions</title>
                  <p>Vitamin D<sub>3</sub>, 2000 IU/d, and marine omega-3 fatty acids, 1 g/d.</p>
                </sec>
                <sec id="ab-zoi220884-8">
                  <title>Main Outcomes and Measures</title>
                  <p>Frailty was measured using a validated 36-item frailty index that includes measures of function, cognition, mood, and comorbidities from annual questionnaires. Change in frailty score from baseline to year 5, according to randomization, using an intention-to-treat protocol, was assessed using repeated measures. Cox proportional hazards regression models assessed incident frailty. In subgroup analysis, an alternative frailty definition, the physical phenotype, was used as a sensitivity analysis.</p>
                </sec>
                <sec id="ab-zoi220884-9">
                  <title>Results</title>
                  <p>Of 25 871 VITAL trial participants randomized, 25 057 had sufficient data to calculate a frailty index. Baseline mean (SD) age was 67.2 (7.0) years, and 12 698 (50.7.%) were women. Mean (SD) frailty score was 0.109 (0.090) (range, 0.00-0.685), and 3174 individuals (12.7%) were frail. During a median 5-year follow-up, mean (SD) frailty scores increased to 0.121 (0.099) (range, 0.00-0.792). Neither vitamin D<sub>3</sub> nor omega-3 fatty acid supplementation affected mean frailty scores over time (mean difference at year 5: vitamin D<sub>3</sub>, −0.0002; <italic>P</italic> = .85; omega-3 fatty acid, −0.0001; <italic>P</italic> = .90) or rate of change in mean frailty score (interaction with time: vitamin D<sub>3</sub>; <italic>P</italic> = .98; omega-3 fatty acid; <italic>P</italic> = .13) Incident frailty remained similar over time (interaction with time: vitamin D<sub>3</sub>, <italic>P</italic> = .90; omega-3 fatty acid; <italic>P</italic> = .32). Results were unchanged using the frailty physical phenotype.</p>
                </sec>
                <sec id="ab-zoi220884-10">
                  <title>Conclusions and Relevance</title>
                  <p>In this ancillary study of the VITAL randomized clinical trial, treatment with vitamin D<sub>3</sub> or omega-3 fatty acid supplementation, compared with placebo, did not affect the rate of frailty change or incidence over time. These results do not support routine use of either vitamin D<sub>3</sub> or omega-3 fatty acid supplementation for frailty prevention in generally healthy community-dwelling older adults not selected for vitamin D<sub>3</sub> deficiency.</p>
                </sec>
                <sec id="ab-zoi220884-11">
                  <title>Trial Registration</title>
                  <p>ClinicalTrials.gov Identifier: <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01169259" ext-link-type="uri">NCT01169259</ext-link></p>
                </sec>
              </abstract>
              <abstract abstract-type="teaser" specific-use="electronic">
                <p>This ancillary study of a randomized clinical trial investigates the effects of vitamin D3 with omega-3 fatty acid supplementation on frailty in older adults.</p>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec id="H1-1-ZOI220884">
              <title>Introduction</title>
              <p>The rapid increase of the worldwide population of aging individuals has led to increased urgency to identify potential preventive strategies for frailty. Frailty is a syndrome of decreased physiologic reserve in the face of external stressors that is associated with an increased risk of morbidity and mortality.<sup><xref rid="zoi220884r1" ref-type="bibr">1</xref>,<xref rid="zoi220884r2" ref-type="bibr">2</xref>,<xref rid="zoi220884r3" ref-type="bibr">3</xref></sup> Although frailty is independent of age, it increases in prevalence with age, with estimates that up to half of adults aged 85 years and older are living with frailty.<sup><xref rid="zoi220884r1" ref-type="bibr">1</xref></sup> Chronic inflammation is a primary hypothesized mechanism leading to frailty.<sup><xref rid="zoi220884r4" ref-type="bibr">4</xref></sup> Whether medications and supplements with anti-inflammatory properties can lower the risk of frailty remains uncertain.<sup><xref rid="zoi220884r1" ref-type="bibr">1</xref>,<xref rid="zoi220884r5" ref-type="bibr">5</xref></sup></p>
              <p>The Vitamin D and Omega-3 (VITAL) trial was conducted to assess the efficacy of vitamin D<sub>3</sub> and omega-3 fatty acid supplementation on the primary outcomes of cancer or cardiovascular disease (CVD).<sup><xref rid="zoi220884r6" ref-type="bibr">6</xref>,<xref rid="zoi220884r7" ref-type="bibr">7</xref></sup> Both of these supplements have anti-inflammatory properties and may have a role in lowering the risk of frailty over time or modifying the trajectory of frailty.<sup><xref rid="zoi220884r1" ref-type="bibr">1</xref>,<xref rid="zoi220884r8" ref-type="bibr">8</xref></sup> Specifically, low serum 25-hydroxyvitamin D (25[OH]D) levels are associated with frailty, potentially as a marker of poor nutrition or through a direct effect on muscle and bone health, both of which are closely linked with frailty.<sup><xref rid="zoi220884r9" ref-type="bibr">9</xref></sup> Observational studies, however, are limited by reverse causation. Studies in mice have suggested that supplementation with vitamin D<sub>3</sub> may slow the development of frailty,<sup><xref rid="zoi220884r10" ref-type="bibr">10</xref></sup> but observational data in humans have been mixed and study data are limited.<sup><xref rid="zoi220884r1" ref-type="bibr">1</xref>,<xref rid="zoi220884r10" ref-type="bibr">10</xref></sup> Omega-3 fatty acids may have a role in prevention of CVD,<sup><xref rid="zoi220884r11" ref-type="bibr">11</xref></sup> which shares a bidirectional association with frailty.<sup><xref rid="zoi220884r12" ref-type="bibr">12</xref></sup> Moreover, some evidence suggests that omega-3 fatty acid supplementation may improve sarcopenia, or age-related muscle loss, which is closely interrelated with frailty.<sup><xref rid="zoi220884r13" ref-type="bibr">13</xref></sup> Therefore, we sought to test the hypothesis that vitamin D<sub>3</sub> and omega-3 fatty acid supplementation would lower the risk of frailty, defined according to 2 leading definitions of frailty, over time in community-dwelling older adults who participated in the VITAL trial.</p>
            </sec>
            <sec id="H1-2-ZOI220884">
              <title>Methods</title>
              <sec id="H2-1-ZOI220884">
                <title>Ethics</title>
                <p>The institutional review board at Partners HealthCare–Brigham and Women’s Hospital approved the trial. The trial protocol is available in <xref rid="note-ZOI220884-1-s" ref-type="supplementary-material">Supplement 1</xref>. The ancillary study protocol is available in <xref rid="note-ZOI220884-1-s" ref-type="supplementary-material">Supplement 2</xref>. All participants provided written informed consent before enrollment. This study follows the Consolidated Standards of Reporting Trials (<ext-link xlink:href="https://www.equator-network.org/reporting-guidelines/consort/" ext-link-type="uri">CONSORT</ext-link>) reporting guideline for trials.<sup><xref rid="zoi220884r14" ref-type="bibr">14</xref></sup></p>
              </sec>
              <sec id="H2-2-ZOI220884">
                <title>Trial Design</title>
                <p>Details of the VITAL trial have been described in detail.<sup><xref rid="zoi220884r6" ref-type="bibr">6</xref>,<xref rid="zoi220884r7" ref-type="bibr">7</xref></sup> Briefly, the VITAL trial was a double-blind, placebo-controlled randomized trial that used a 2 × 2 factorial design to test the efficacy of daily supplementation with vitamin D<sub>3</sub>, 2000 IU, and/or marine omega-3 fatty acids, 840 mg (including eicosapentaenoic acid, 460 mg, and docosahexaenoic acid, 380 mg,) for preventing cancer and CVD. The trial enrolled 25 871 men aged ≥50 years and women aged ≥55 years free of CVD and cancer at baseline. Patients were recruited across all 50 US states from November 2011 to March 2014 and followed up through December 31, 2017. Data analysis for the ancillary study was conducted from December 1, 2019, to March 30, 2022.</p>
                <p>To capture updated information on health status, lifestyle, and other variables, participants completed questionnaires at baseline (prerandomization), 6 months after the trial started, and then annually throughout the trial. A subgroup of participants who lived within driving distance of Boston, Massachusetts, were invited to participate in in-person assessments at the Clinical and Translational Science Center at Brigham and Women’s Hospital. These visits included a clinical examination that incorporated markers of frailty at baseline, year 2, and year 4.</p>
              </sec>
              <sec id="H2-3-ZOI220884">
                <title>Outcome Assessment</title>
                <p>The primary outcome of this ancillary study was change in frailty score over time. Although several tools can be used to measure frailty,<sup><xref rid="zoi220884r1" ref-type="bibr">1</xref>,<xref rid="zoi220884r15" ref-type="bibr">15</xref></sup> in the VITAL trial, frailty was primarily defined according to the well-validated, cumulative deficit model developed by Rockwood and colleagues.<sup><xref rid="zoi220884r16" ref-type="bibr">16</xref>,<xref rid="zoi220884r17" ref-type="bibr">17</xref></sup> The Rockwood frailty index (FI) has been used in prospective and retrospective studies of diverse populations around the world<sup><xref rid="zoi220884r18" ref-type="bibr">18</xref>,<xref rid="zoi220884r19" ref-type="bibr">19</xref>,<xref rid="zoi220884r20" ref-type="bibr">20</xref>,<xref rid="zoi220884r21" ref-type="bibr">21</xref>,<xref rid="zoi220884r22" ref-type="bibr">22</xref></sup> and is a particularly useful tool to characterize older adult populations in clinical trials.<sup><xref rid="zoi220884r23" ref-type="bibr">23</xref>,<xref rid="zoi220884r24" ref-type="bibr">24</xref>,<xref rid="zoi220884r25" ref-type="bibr">25</xref></sup> This theory of frailty posits that deficits in health accumulate over the life span. These deficits can be counted to generate an FI and determine an individual’s frailty status.</p>
                <p>To be included in the FI, variables must (1) be related to health status, (2) increase in prevalence with age, (3) not saturate in the population (eg, presbyopia), and (4) include a range of systems, such as cognition, function, and morbidity.<sup><xref rid="zoi220884r17" ref-type="bibr">17</xref></sup> For repeated measures, such as in this study, the identical items should be assessed at each frailty measurement. A minimum of 30 variables are typically included, and scores range from 0 to 1, with the 99th percentile for most populations 0.7.<sup><xref rid="zoi220884r1" ref-type="bibr">1</xref>,<xref rid="zoi220884r17" ref-type="bibr">17</xref></sup> For example, an individual with 6 of 30 possible deficits will have a score of 0.2. Population studies suggest that community-dwelling older adults accumulate deficits at a rate of 3% per year,<sup><xref rid="zoi220884r26" ref-type="bibr">26</xref></sup> and clinically meaningful annual changes in an FI score are 0.019 (small change) and 0.057 (large change).<sup><xref rid="zoi220884r27" ref-type="bibr">27</xref></sup> However, in clinical trials, meaningful annual increases as small as 0.005 have been described.<sup><xref rid="zoi220884r28" ref-type="bibr">28</xref></sup> Based on prior literature, frailty scores of 0 to 0.1 are considered nonfrail, 0.1 to 0.2 are prefrail, and higher than 0.2 are frail.<sup><xref rid="zoi220884r23" ref-type="bibr">23</xref></sup></p>
                <p>A total of 36 variables were included (eTable 1 in <xref rid="note-ZOI220884-1-s" ref-type="supplementary-material">Supplement 3</xref>). Variables included in the FI covered domains related to functional status, mood, and comorbidities. The Short-Form 36 was used to extract self-reported information on health status, function, and mood. Annual questionnaires captured information on comorbidities and cognition. Variables are not weighted, rather, within each person, deficits will autoweight. For example, if an individual has hearing loss and arthritis, but no other deficits, they are not frail. Another individual with these same conditions who also has other deficits, such as function or mood, would be prefrail or frail.<sup><xref rid="zoi220884r16" ref-type="bibr">16</xref>,<xref rid="zoi220884r29" ref-type="bibr">29</xref></sup> Participants missing more than 10% of the items required for the FI were excluded. When possible, logical imputation was used to fill in missing data. For example, if an individual reported no trouble climbing several flights of stairs but did not indicate whether they could climb 1 flight of stairs, they were assumed to have no difficulty. Data for self-reported items, such as function, were carried forward from the previous questionnaire if missing in the following year (maximum carry forward 1 year). For validated diagnoses, such as heart failure, once a diagnosis was confirmed, it was carried forward. The only exceptions were for anemia or depression, which could change based on reported diagnoses. Data were available to calculate an FI at baseline and years 3, 4, and 5. In year 5, questionnaires were sent to only 16 639 VITAL trial participants, and 14 287 had sufficient data to calculate frailty in year 5.</p>
                <p>In a subgroup of 1054 participants, the Fried physical phenotype was measured at baseline and at follow-up years 2 and 4. The physical phenotype of frailty includes 5 interrelated variables: greater than or equal to 2.3 kg of unintentional weight loss in the previous year, self-reported exhaustion, low energy expenditure according to kilocalories or energy, slow walking speed, and weak grip strength<sup><xref rid="zoi220884r2" ref-type="bibr">2</xref></sup> (eTable 2 in <xref rid="note-ZOI220884-1-s" ref-type="supplementary-material">Supplement 3</xref>).</p>
              </sec>
              <sec id="H2-4-ZOI220884">
                <title>Other Covariates</title>
                <p>Several demographic variables and risk factors were assessed at baseline, including age; sex; race and ethnicity, as required by the funder; smoking status; body mass index (BMI) (categorized as &lt;25, 25 to &lt;30, and ≥30 [calculated as weight in kilograms divided by height in meters squared]); alcohol use; baseline 25(OH)D level (dichotomized at &lt;20 vs ≥20 ng/mL); and baseline dietary fish consumption (dichotomized at &lt;1.5 vs ≥1.5 servings/week).<sup><xref rid="zoi220884r6" ref-type="bibr">6</xref>,<xref rid="zoi220884r7" ref-type="bibr">7</xref></sup></p>
              </sec>
              <sec id="H2-5-ZOI220884">
                <title>Statistical Analysis</title>
                <p>For this ancillary study, we expected a minimum increase in the FI of approximately 0.01 during 5 years for participants randomized to placebo, 5% loss to follow-up per year, and n = 25 000. Given these factors, we would have greater than 90% power provided that randomization to vitamin D<sub>3</sub> or omega-3 fatty acids slows the rate of deficit accumulation by at least 40% (ie, reduces the mean FI increase during 5 years from 0.01 to 0.006). Baseline characteristics were compared for each treatment group to confirm balance by randomization was maintained.</p>
                <p>The association between the FI and risk of mortality over the duration of follow-up was assessed using Cox proportional hazards regression to show validity of the FI, according to standard procedures.<sup><xref rid="zoi220884r17" ref-type="bibr">17</xref></sup> Because there was an a priori assumption of no interaction between vitamin D<sub>3</sub> and omega-3 fatty acids, all analyses examined the pooled main effects of each supplement on change in frailty over time. The primary outcome was a continuous FI score over the duration of the trial according to randomization to either vitamin D<sub>3</sub> or omega-3 fatty acids, using intention-to-treat analysis. Repeated-measures models with an unstructured covariance matrix were fit using the SAS PROC MIXED procedure. The associations between vitamin D<sub>3</sub> and omega-3 fatty acid treatment and change in FI score over time (baseline and years 3, 4, and 5) were assessed using interaction terms between treatment and time. We assessed adjusted means within each treatment group comparing the vitamin D<sub>3</sub> and omega-3 fatty acid groups with placebo groups and adjusted mean differences in FI level change for each follow-up time point. This analysis was repeated for the subgroup that had the Fried definition of frailty available.</p>
                <p>In examining incident frailty, those with an FI score greater than 0.21 were excluded. Participants were followed up until the estimated frailty level was greater than 0.21 at the reported follow-up questionnaire date, death, or the end of the trial, whichever came first. Cox proportional hazards regression models were used to estimate hazard ratios and 95% CIs for vitamin D<sub>3</sub> or omega-3 fatty acids vs placebo, adjusting for age and sex. Cumulative incidence curves were used to compare the vitamin D<sub>3</sub>, omega-3, and placebo groups at each time point, with linear interpolation between points.</p>
                <p>Secondarily, the following prespecified interactions were tested for both vitamin D<sub>3</sub> and omega-3 fatty acids: median age (66.8 years), race and ethnicity, and sex. In addition, for vitamin D<sub>3</sub>, interactions with baseline 25(OH)D and BMI were assessed. For omega-3 fatty acid, interaction with baseline fish consumption was calculated.</p>
                <p>Analyses were conducted using SAS software, version 9.4 (SAS Institute Inc). Statistical significance was set at 2-sided <italic>P</italic> &lt; .05.</p>
              </sec>
            </sec>
            <sec id="H1-3-ZOI220884">
              <title>Results</title>
              <p>At baseline, data were available to calculate frailty for approximately 97% of VITAL trial participants (n = 25 057) (<xref rid="zoi220884f1" ref-type="fig">Figure 1</xref>) At years 3, 4, and 5, data were available for 22 761 (88%), 21 449 (83%), and 14 287 (55%) participants. Mean (SD) age at baseline was 67.2 (7.0) years, 12 698 were women (50.7.%). Self-reported racial and ethnic groups comprised 357 (1.4%) Asian/Pacific Islander, 4842 (19.3%) Black or African American, 357 (1.4%) Native American/Alaskan Native, 962 (3.8%) non-Black Hispanic, 17 632 (70.4%) non-Hispanic White, and 497 (2.0%) other or unknown individuals. Baseline demographic and other characteristics did not differ substantially by treatment group (<xref rid="zoi220884t1" ref-type="table">Table</xref>). Mean (SD) baseline FI was 0.109 (0.090) (range, 0.00-0.685), and 3174 individuals (12.7%) in the cohort were frail, as defined by an FI score greater than 0.21, 7285 (29%) were prefrail (FI score, 0.1-0.21), and 14 598 (58%) were not frail (FI score, &lt;0.1). Baseline distribution of the FI scores for the overall trial and according to vitamin D<sub>3</sub> or omega-3 fatty acid randomization status are shown in eFigure 1 and eFigure 2 in <xref rid="note-ZOI220884-1-s" ref-type="supplementary-material">Supplement 3</xref>. Baseline characteristics according to frailty category are reported in eTable 3 in <xref rid="note-ZOI220884-1-s" ref-type="supplementary-material">Supplement 3</xref>. Over a median of 5.3 years of follow-up, mean (SD) FI scores increased to 0.121 (0.099) (range, 0.00-0.792) and a total of 2487 (11.3%) became frail according to the FI score during follow-up. To validate the FI, the association between FI level and mortality was assessed, and a higher level of frailty was associated with an increased risk of mortality over time<sup><xref rid="zoi220884r17" ref-type="bibr">17</xref></sup> (eFigure 3 in <xref rid="note-ZOI220884-1-s" ref-type="supplementary-material">Supplement 3</xref>).</p>
              <fig position="float" id="zoi220884f1" fig-type="figure">
                <label>Figure 1. </label>
                <caption>
                  <title>Participant Flow Diagram</title>
                  <p>EPA-DHA indicates eicosapentaenoic acid and docosahexaenoic acid.</p>
                </caption>
                <graphic xlink:href="jamanetwopen-e2231206-g001" position="float"/>
              </fig>
              <table-wrap position="float" id="zoi220884t1">
                <label>Table. </label>
                <caption>
                  <title>Baseline Characteristics of 25 057 Participants in the VITAL Trial With Sufficient Frailty Data Available<xref rid="zoi220884t1n1" ref-type="table-fn"><sup>a</sup></xref></title>
                </caption>
                <table frame="hsides" rules="groups">
                  <col width="36.61%" span="1"/>
                  <col width="18.06%" span="1"/>
                  <col width="15.72%" span="1"/>
                  <col width="15.01%" span="1"/>
                  <col width="14.6%" span="1"/>
                  <thead>
                    <tr>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Characteristic</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Vitamin D<sub>3</sub> and omega-3 fatty acids (n = 6251)</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Vitamin D<sub>3</sub> only (n = 6246)</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Omega-3 only (n = 6278)</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Placebo only (n = 6282)</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age, mean (SD), y</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">67.2 (7.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">67.1 (7.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">67.2 (7.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">67.2 (7.1)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex, No. (%)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3170 (50.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3165 (50.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3182 (50.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3181 (50.6)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3081 (49.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3081 (49.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3096 (49.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3101 (49.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Racial and ethnic group, No. (%)<xref rid="zoi220884t1n2" ref-type="table-fn"><sup>b</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Asian/Pacific Islander</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">92 (1.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">82 (1.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">91 (1.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">92 (1.5)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Black or African American</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1207 (19.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1214 (19.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1206 (19.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1215 (19.8)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Native American/Alaskan Native</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">92 (1.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">82 (1.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">91 (1.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">92 (1.5)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Non-Black Hispanic</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"> 233 (3.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">257 (4.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">236 (3.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">236 (3.8)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Non-Hispanic White</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"> 4407 (72.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4375 (71.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4430 (72.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4420 (71.9)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other or unknown<xref rid="zoi220884t1n3" ref-type="table-fn"><sup>c</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">122 (2.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">125 (2.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">118 (1.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">132 (2.2)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">BMI, mean (SD)<xref rid="zoi220884t1n4" ref-type="table-fn"><sup>d</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">28.1 (5.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">28.1 (5.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">28.1 (5.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">28.0 (5.8)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Current smoker, No. (%)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"> 439 (7.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">456 (7.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">449 (7.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">436 (7.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Daily alcohol use, No. (%)<xref rid="zoi220884t1n5" ref-type="table-fn"><sup>e</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1588 (25.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1626 (26.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1664 (26.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1636 (26.3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Current regular aspirin use, No. (%)<xref rid="zoi220884t1n6" ref-type="table-fn"><sup>f</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2808 (45.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2801 (45.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2832 (45.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2862 (46.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Current use of statins, No. (%)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2212 (35.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2197 (35.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2157 (34.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2122 (34.1)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Baseline 25(OH)D levels, mean (SD), ng/mL</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">31.0 (10.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">30.8 (9.9)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Baseline dietary fish consumption ≥1.5 servings/wk, No. (%)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2906 (46.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2878 (46.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2906 (46.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2947 (47.3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Leisure-time physical activity and stair climbing, total metabolic equivalent of task -hours per week, median (IQR)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">15.5 (4.6-31.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">15.2 (4.5-31.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">15.5 (4.7-31.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">15.7 (4.7-32.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Frailty Index, median (IQR)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.08 (0.04-0.15)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.08 (0.05-0.14)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.08 (0.05-0.14)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.08 (0.05-0.15)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <p>Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); NA, not applicable; 25(OH)D, 25-hydroxyvitamin D; VITAL, Vitamin D and Omega-3.</p>
                  <p>SI conversion: to convert 25(OH)D to nanomoles per liter, multiply by 2.496.</p>
                  <fn id="zoi220884t1n1">
                    <label>
                      <sup>a</sup>
                    </label>
                    <p>There were no significant differences between groups regarding the baseline characteristics.</p>
                  </fn>
                  <fn id="zoi220884t1n2">
                    <label>
                      <sup>b</sup>
                    </label>
                    <p>Race and ethnic group were reported by participants.</p>
                  </fn>
                  <fn id="zoi220884t1n3">
                    <label>
                      <sup>c</sup>
                    </label>
                    <p>Patients self-reported other or unknown race or ethnicity (n = 497).</p>
                  </fn>
                  <fn id="zoi220884t1n4">
                    <label>
                      <sup>d</sup>
                    </label>
                    <p>Data were missing for 2.3% of the participants. For vitamin D<sub>3</sub> and omega-3 fatty acids, n=6104; vitamin D<sub>3</sub> only, n=6105; omega-3 only, n=6121; and placebo only, n=6139.</p>
                  </fn>
                  <fn id="zoi220884t1n5">
                    <label>
                      <sup>e</sup>
                    </label>
                    <p>Alcohol use greater than or equal to 1 drink per day of wine (150-mL glass), liquor (shot), or beer (bottle, can, or glass).</p>
                  </fn>
                  <fn id="zoi220884t1n6">
                    <label>
                      <sup>f</sup>
                    </label>
                    <p>At least monthly.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <sec id="H2-6-ZOI220884">
                <title>Main Findings</title>
                <p>Neither vitamin D<sub>3</sub> nor omega-3 fatty acid supplementation affected mean frailty scores over time (vitamin D<sub>3</sub> mean difference, −0.0002; <italic>P</italic> = .85; and omega-3 fatty acid mean difference, −0.0001; <italic>P</italic> = .90) (eTable 4 in <xref rid="note-ZOI220884-1-s" ref-type="supplementary-material">Supplement 3</xref>) or the rate of change in FI score over time (interaction with time: vitamin D<sub>3</sub>; <italic>P</italic> = .98; omega-3 fatty acid; <italic>P</italic> = .13) (<xref rid="zoi220884f2" ref-type="fig">Figure 2</xref>). Incident frailty remained similar between randomization groups over time (interaction with time: <italic>P</italic> = .90 for vitamin D<sub>3</sub> and <italic>P</italic> = .32 for omega-3 fatty acid) (eFigure 4A and eFigure 4B in <xref rid="note-ZOI220884-1-s" ref-type="supplementary-material">Supplement 3</xref>) Results were unchanged after adjusting models for baseline age, sex, and the other randomized intervention.</p>
                <fig position="float" id="zoi220884f2" fig-type="figure">
                  <label>Figure 2. </label>
                  <caption>
                    <title>Change in Mean Frailty Levels During the Study</title>
                    <p>A, Change in mean frailty levels in vitamin D group compared with placebo. B, Change in mean frailty levels in omega-3 fatty acids group compared with placebo. Error bars indicate 95% CI.</p>
                  </caption>
                  <graphic xlink:href="jamanetwopen-e2231206-g002" position="float"/>
                </fig>
              </sec>
              <sec id="H2-7-ZOI220884">
                <title>Interaction With Vitamin D<sub>3</sub> Supplementation</title>
                <p>Older participants in the trial had a greater increase in the FI score over the follow-up period; however, there was no interaction between vitamin D<sub>3</sub> and age (<italic>P</italic> = .52 for interaction). At baseline, women had a higher mean FI score (0.13 vs 0.09 in men); however, there was no significant interaction between vitamin D<sub>3</sub> and sex (<italic>P</italic> = .37 for interaction). Black individuals had higher frailty scores at baseline compared with White individuals and those identifying as other race, but there was no significant interaction between vitamin D<sub>3</sub> and race (<italic>P</italic> &gt; .99 for interaction). Participants with baseline 25(OH)D levels less than 20 ng/mL had a higher baseline frailty score (0.13 vs 0.10), yet there was no significant interaction with vitamin D<sub>3</sub> (<italic>P</italic> = .33 for interaction). Participants with a BMI less than 25 and 25 to 30 had mean frailty scores at baseline in the nonfrail range, compared with those with a BMI greater than or equal to 30 with FI scores in the high prefrail range; however, there was no interaction between vitamin D<sub>3</sub> and BMI (<italic>P</italic> = .22 for interaction) (<xref rid="zoi220884f3" ref-type="fig">Figure 3</xref>; eFigure 5 in <xref rid="note-ZOI220884-1-s" ref-type="supplementary-material">Supplement 3</xref>).</p>
                <fig position="float" id="zoi220884f3" fig-type="figure">
                  <label>Figure 3. </label>
                  <caption>
                    <title>Mean Change in Frailty Score at Each Year Since Randomization According to Vitamin D<sub>3</sub> and Placebo Groups by Baseline Subgroups</title>
                    <p>BMI indicates body mass index (calculated as weight in kilograms divided by height in meters squared; 25(OH)D, 25-hydroxyvitamin D.</p>
                    <p><sup>a</sup>Self-reported Asian/Pacific Islander, Native American/Alaskan Native, non-Black Hispanic, and unknown race and ethnicity.</p>
                  </caption>
                  <graphic xlink:href="jamanetwopen-e2231206-g003" position="float"/>
                </fig>
              </sec>
              <sec id="H2-8-ZOI220884">
                <title>Interaction With Omega-3 Fatty Acid Supplementation</title>
                <p>There were no significant interactions between omega-3 fatty acids and frailty scores by sex (<italic>P</italic> = .74) or race and ethnicity (<italic>P</italic> = .53 for interaction). There was a significant interaction by age (<italic>P</italic> = .01). Frailty scores at baseline were similar between participants who reported eating 1.5 or more servings of fish per week or less than 1.5 servings per week. There was no interaction between baseline fish consumption and omega-3 fatty acid supplementation on frailty scores (<italic>P</italic> = .15 for interaction) (<xref rid="zoi220884f4" ref-type="fig">Figure 4</xref>; eFigure 6 in <xref rid="note-ZOI220884-1-s" ref-type="supplementary-material">Supplement 3</xref>).</p>
                <fig position="float" id="zoi220884f4" fig-type="figure">
                  <label>Figure 4. </label>
                  <caption>
                    <title>Mean Change in Frailty Score at Each Year Since Randomization According to Omega-3 Fatty Acid and Placebo Groups by Baseline Subgroups</title>
                    <p><sup>a</sup>Self-reported Asian/Pacific Islander, Native American/Alaskan Native, non-Black Hispanic, and unknown race and ethnicity.</p>
                  </caption>
                  <graphic xlink:href="jamanetwopen-e2231206-g004" position="float"/>
                </fig>
              </sec>
              <sec id="H2-9-ZOI220884">
                <title>Sensitivity Analysis</title>
                <p>Data were available to define frailty according to the Fried physical phenotype for 1054 participants. Baseline characteristics for this subgroup are reported in eTable 5 in <xref rid="note-ZOI220884-1-s" ref-type="supplementary-material">Supplement 3</xref> and are similar to those of the population in the main trial. Results remained largely unchanged when the Fried definition was used (eTable 6A and B and eFigure 7 and eFigure 8 in <xref rid="note-ZOI220884-1-s" ref-type="supplementary-material">Supplement 3</xref>).</p>
              </sec>
            </sec>
            <sec id="H1-4-ZOI220884">
              <title>Discussion</title>
              <p>In this ancillary study of the VITAL randomized clinical trial of community-dwelling participants aged 50 years and older, neither vitamin D<sub>3</sub>, 2000 IU/d, nor omega-3 fatty acid, 1 g/d, supplementation, compared with placebo, affected frailty levels or incidence change in frailty scores over 5 years of treatment. Results did not change significantly after considering interactions by sex, race and ethnicity, BMI, baseline serum 25(OH)D levels, and weekly fish consumption, or when using an alternative definition of frailty, except for a significant interaction by age for omega-3 fatty acid supplementation. These results do not support the routine supplementation of healthy community-dwelling adults with vitamin D<sub>3</sub> or omega-3 fatty acids for the prevention of frailty.</p>
              <p>Frailty, a syndrome of diminished physiologic reserve, is caused by inflammation and worsened by poor nutrition.<sup><xref rid="zoi220884r1" ref-type="bibr">1</xref>,<xref rid="zoi220884r30" ref-type="bibr">30</xref>,<xref rid="zoi220884r31" ref-type="bibr">31</xref></sup> Observational data have shown an association between malnutrition and increased risk of frailty, and supplementation with micronutrients and macronutrients has been hypothesized as a potential approach for both prevention and treatment of frailty.<sup><xref rid="zoi220884r1" ref-type="bibr">1</xref>,<xref rid="zoi220884r9" ref-type="bibr">9</xref></sup> Moreover, sarcopenia and decline in function are closely related, and perhaps on the pathway to frailty.<sup><xref rid="zoi220884r32" ref-type="bibr">32</xref></sup> Frailty is differentiated from sarcopenia as a multisystem impairment leading to an increased vulnerability. Low 25(OH)D concentrations have been implicated in sarcopenia, in part through the presence of 1,25(OH)<sub>2</sub>D receptors in skeletal muscle that lead to alterations in contractility and reduced muscle synthesis.<sup><xref rid="zoi220884r9" ref-type="bibr">9</xref>,<xref rid="zoi220884r13" ref-type="bibr">13</xref></sup> Low concentrations of omega-3 fatty acids have similarly been associated with an increased risk of frailty and sarcopenia.<sup><xref rid="zoi220884r13" ref-type="bibr">13</xref></sup> It is therefore tempting to consider supplementation with vitamin D<sub>3</sub> and omega-3 fatty acids, both of which have anti-inflammatory properties, as strategies to lower the risk of frailty and sarcopenia.<sup><xref rid="zoi220884r9" ref-type="bibr">9</xref>,<xref rid="zoi220884r13" ref-type="bibr">13</xref></sup> However, the reported findings in this trial on participants largely replete in vitamin D<sub>3</sub> do not support this practice. It is possible that in a less-nourished population, vitamin D<sub>3</sub> and omega-3 fatty acids may have a role in prevention of frailty. Regular exercise and the Mediterranean diet are proven strategies for the prevention of frailty and should be encouraged for older adults.<sup><xref rid="zoi220884r1" ref-type="bibr">1</xref>,<xref rid="zoi220884r28" ref-type="bibr">28</xref>,<xref rid="zoi220884r33" ref-type="bibr">33</xref>,<xref rid="zoi220884r34" ref-type="bibr">34</xref></sup></p>
              <p>Similar to the VITAL trial, the DO-HEALTH trial randomized community-dwelling older adults in Europe aged 70 years and older in a 2 × 2 × 2 factorial design to vitamin D<sub>3</sub>, 2000 IU/d, omega-3 fatty acid, 1 g/d, and a strength-training exercise program.<sup><xref rid="zoi220884r35" ref-type="bibr">35</xref></sup> Among several primary outcomes, there was no statistically significant difference in function, measured using the short physical performance battery in participants randomized to vitamin D<sub>3</sub> or omega-3 fatty acid compared with placebo. The short physical performance battery, which includes measurement of gait speed, balance, and chair stands, has also been used as a measure of frailty.<sup><xref rid="zoi220884r36" ref-type="bibr">36</xref></sup> Compared with the VITAL trial, DO-HEALTH focused on an older population and follow-up was shorter at 3 years. A possible lack of efficacy for vitamin D<sub>3</sub> and omega-3 fatty acids for functional outcomes could have been attributed to the need to begin supplementation earlier in life and continue treatment for longer durations. Results from the VITAL trial, with a younger population and 5.3 years of follow-up, suggest that, even at younger ages and longer duration, there is no benefit of vitamin D<sub>3</sub> or omega-3 fatty acid supplementation for frailty prevention.</p>
              <p>A meta-analysis of 29 randomized clinical trials of vitamin D supplementation that enrolled a total of 5533 participants reported a small increase in overall muscle strength (standard difference in means of 0.17; 95% CI, 0.03-0.31; <italic>P</italic> = .02), although heterogeneity was high (<italic>I</italic><sup>2</sup> = 77.7%).<sup><xref rid="zoi220884r37" ref-type="bibr">37</xref></sup> Changes were most notable among participants whose baseline serum 25(OH)D levels were less than 12 ng/mL (to convert to nanomoles per liter, multiply by 2.496). In addition, low serum 25(OHD levels are associated with an increased risk of falls and osteoporotic fractures, which can be an antecedent to or a marker of frailty. However, supplementation with vitamin D<sub>3</sub> for primary prevention of falls has not reduced the risk of falls and is not routinely recommended.<sup><xref rid="zoi220884r38" ref-type="bibr">38</xref>,<xref rid="zoi220884r39" ref-type="bibr">39</xref></sup> In the VITAL trial cohort, supplementation with vitamin D<sub>3</sub> vs placebo did not reduce falls.<sup><xref rid="zoi220884r40" ref-type="bibr">40</xref></sup> The data in the present study are in line with results to date that do not suggest a role of vitamin D<sub>3</sub> for physical performance or frailty prevention.</p>
              <p>Omega-3 polyunsaturated fatty acids are postulated to have anabolic effects through activation of the mTOR signaling pathway and lowering insulin resistance, both of which are implicated in sarcopenia, and CVD.<sup><xref rid="zoi220884r13" ref-type="bibr">13</xref>,<xref rid="zoi220884r41" ref-type="bibr">41</xref></sup> In the VITAL trial, omega-3 fatty acid supplementation did not lower the overall incidence of a major CVD event (hazard ratio, 0.92; 95% CI, 0.80-1.06; <italic>P</italic> = .24), although there was a significant effect on lower risk of myocardial infarction, fatal myocardial infarction, and total coronary heart disease. In a meta-analysis of 13 trials that included a total of 127 477 participants followed up for an average of 5 years, there was a significantly lower risk of CVD events in those randomized to omega-3 fatty acids vs placebo.<sup><xref rid="zoi220884r11" ref-type="bibr">11</xref></sup> Furthermore, the Prevention with Mediterranean Diet (PREDIMED) trial demonstrated that high adherence to a Mediterranean diet, which is high in fish consumption, was associated with a lower risk of frailty in post-hoc analysis.<sup><xref rid="zoi220884r42" ref-type="bibr">42</xref></sup> These data have led to the hypothesis that omega-3 fatty acid supplementation may also prevent frailty.<sup><xref rid="zoi220884r43" ref-type="bibr">43</xref></sup> The data in the present study do not support the use of omega-3 fatty acids for prevention of frailty; in fact, in subgroup analyses, there was a significant interaction for age favoring placebo for individuals aged 67 years and older. These subgroup data should be interpreted with caution.</p>
              <p>The lack of benefit of vitamin D<sub>3</sub> or omega-3 fatty acid supplementation on frailty in the VITAL trial may be due to the overall healthy population, as evidenced by only 13% with frailty at baseline. In the general population of older adults of similar ages, prevalence rates of frailty approach 25%, and the rate in those with CVD can be as high as 60%.<sup><xref rid="zoi220884r12" ref-type="bibr">12</xref>,<xref rid="zoi220884r44" ref-type="bibr">44</xref></sup> It is possible that persons who will benefit the most from supplementation with vitamin D<sub>3</sub> and omega-3 fatty acids are more vulnerable individuals, such as those no longer able to live in the community.</p>
              <sec id="H2-10-ZOI220884">
                <title>Strengths and Limitations</title>
                <p>This study has strengths. This was a large ancillary study of a randomized clinical trial of community-dwelling older adults that included diverse participants with high follow-up rates and adherence to the study protocol. The use of a well-validated frailty definition that has been applied in other trials is a strength, as is the sensitivity analysis that used an alternative leading definition of frailty. We specifically used these 2 leading definitions of frailty because each identifies somewhat different populations of older adults with frailty and are predicated on different theories of frailty.<sup><xref rid="zoi220884r45" ref-type="bibr">45</xref></sup> Moreover, it is possible that an intervention may affect cumulative deficit frailty differently than phenotypic frailty.<sup><xref rid="zoi220884r28" ref-type="bibr">28</xref>,<xref rid="zoi220884r46" ref-type="bibr">46</xref></sup> The consistent results in this study suggest that there was no effect of either intervention on frailty, regardless of the definition used. Mean follow-up was more than 5 years, with sufficient time expected to see changes in frailty scores.</p>
                <p>The study has limitations. The doses used in the trial may not have been optimal for prevention of frailty, and only a single dose was studied. Rates of frailty were lower than in the general population, suggesting an overall healthier cohort and possible healthy volunteer bias. As a result, the study does not generalize to noncommunity dwelling older adults who are the most vulnerable and at risk of poor outcomes from frailty. In addition, direct measures of function and frailty status, such as gait speed, were available only in a subgroup of participants, although the FI score included multiple self-reported items related to functional status.</p>
              </sec>
            </sec>
            <sec id="H1-5-ZOI220884">
              <title>Conclusions</title>
              <p>In this ancillary study to the VITAL trial, treatment with vitamin D<sub>3</sub> and/or omega-3 fatty acids, compared with placebo did not affect the frailty scores or the incidence of frailty over time. These results do not support the routine use of either vitamin D<sub>3</sub> or omega-3 fatty acid supplementation for prevention of frailty in healthy, community-dwelling older adults.</p>
            </sec>
          </body>
          <back>
            <ref-list id="REF-ZOI220884">
              <title>References</title>
              <ref id="zoi220884r1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Clegg</surname><given-names>A</given-names></string-name>, <string-name><surname>Young</surname><given-names>J</given-names></string-name>, <string-name><surname>Iliffe</surname><given-names>S</given-names></string-name>, <string-name><surname>Rikkert</surname><given-names>MO</given-names></string-name>, <string-name><surname>Rockwood</surname><given-names>K</given-names></string-name></person-group>. <article-title>Frailty in elderly people</article-title>. <source>Lancet</source>. <year>2013</year>;<volume>381</volume>(<issue>9868</issue>):<fpage>752</fpage>-<lpage>762</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(12)62167-9</pub-id><?supplied-pmid 23395245?><pub-id pub-id-type="pmid">23395245</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Fried</surname><given-names>LP</given-names></string-name>, <string-name><surname>Tangen</surname><given-names>CM</given-names></string-name>, <string-name><surname>Walston</surname><given-names>J</given-names></string-name>, <etal/>; <collab>Cardiovascular Health Study Collaborative Research Group</collab></person-group>. <article-title>Frailty in older adults: evidence for a phenotype</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2001</year>;<volume>56</volume>(<issue>3</issue>):<fpage>M146</fpage>-<lpage>M156</lpage>. doi:<pub-id pub-id-type="doi">10.1093/gerona/56.3.M146</pub-id><?supplied-pmid 11253156?><pub-id pub-id-type="pmid">11253156</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Rockwood</surname><given-names>K</given-names></string-name></person-group>. <article-title>Conceptual models of frailty: accumulation of deficits</article-title>. <source>Can J Cardiol</source>. <year>2016</year>;<volume>32</volume>(<issue>9</issue>):<fpage>1046</fpage>-<lpage>1050</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cjca.2016.03.020</pub-id><?supplied-pmid 27402367?><pub-id pub-id-type="pmid">27402367</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Franceschi</surname><given-names>C</given-names></string-name>, <string-name><surname>Campisi</surname><given-names>J</given-names></string-name></person-group>. <article-title>Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2014</year>;<volume>69</volume>(<issue>suppl 1</issue>):<fpage>S4</fpage>-<lpage>S9</lpage>. doi:<pub-id pub-id-type="doi">10.1093/gerona/glu057</pub-id><?supplied-pmid 24833586?><pub-id pub-id-type="pmid">24833586</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Tessier</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Chevalier</surname><given-names>S</given-names></string-name></person-group>. <article-title>An update on protein, leucine, omega-3 fatty acids, and vitamin D in the prevention and treatment of sarcopenia and functional decline</article-title>. <source>Nutrients</source>. <year>2018</year>;<volume>10</volume>(<issue>8</issue>):<elocation-id>E1099</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/nu10081099</pub-id><?supplied-pmid 30115829?><pub-id pub-id-type="pmid">30115829</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Manson</surname><given-names>JE</given-names></string-name>, <string-name><surname>Cook</surname><given-names>NR</given-names></string-name>, <string-name><surname>Lee</surname><given-names>IM</given-names></string-name>, <etal/>; <collab>VITAL Research Group</collab></person-group>. <article-title>Marine n-3 fatty acids and prevention of cardiovascular disease and cancer</article-title>. <source>N Engl J Med</source>. <year>2019</year>;<volume>380</volume>(<issue>1</issue>):<fpage>23</fpage>-<lpage>32</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1811403</pub-id><?supplied-pmid 30415637?><pub-id pub-id-type="pmid">30415637</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Manson</surname><given-names>JE</given-names></string-name>, <string-name><surname>Cook</surname><given-names>NR</given-names></string-name>, <string-name><surname>Lee</surname><given-names>IM</given-names></string-name>, <etal/>; <collab>VITAL Research Group</collab></person-group>. <article-title>Vitamin D supplements and prevention of cancer and cardiovascular disease</article-title>. <source>N Engl J Med</source>. <year>2019</year>;<volume>380</volume>(<issue>1</issue>):<fpage>33</fpage>-<lpage>44</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1809944</pub-id><?supplied-pmid 30415629?><pub-id pub-id-type="pmid">30415629</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Vellas</surname><given-names>B</given-names></string-name>, <string-name><surname>Sourdet</surname><given-names>S</given-names></string-name></person-group>. <article-title>Prevention of frailty in aging</article-title>. <source>J Frailty Aging</source>. <year>2017</year>;<volume>6</volume>(<issue>4</issue>):<fpage>174</fpage>-<lpage>177</lpage>.<?supplied-pmid 29165531?><pub-id pub-id-type="pmid">29165531</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Artaza-Artabe</surname><given-names>I</given-names></string-name>, <string-name><surname>Sáez-López</surname><given-names>P</given-names></string-name>, <string-name><surname>Sánchez-Hernández</surname><given-names>N</given-names></string-name>, <string-name><surname>Fernández-Gutierrez</surname><given-names>N</given-names></string-name>, <string-name><surname>Malafarina</surname><given-names>V</given-names></string-name></person-group>. <article-title>The relationship between nutrition and frailty: effects of protein intake, nutritional supplementation, vitamin D and exercise on muscle metabolism in the elderly—a systematic review</article-title>. <source>Maturitas</source>. <year>2016</year>;<volume>93</volume>:<fpage>89</fpage>-<lpage>99</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.maturitas.2016.04.009</pub-id><?supplied-pmid 27125943?><pub-id pub-id-type="pmid">27125943</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Seldeen</surname><given-names>KL</given-names></string-name>, <string-name><surname>Berman</surname><given-names>RN</given-names></string-name>, <string-name><surname>Pang</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Vitamin D insufficiency reduces grip strength, grip endurance and increases frailty in aged C57Bl/6J mice</article-title>. <source>Nutrients</source>. <year>2020</year>;<volume>12</volume>(<issue>10</issue>):<elocation-id>E3005</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/nu12103005</pub-id><?supplied-pmid 33007912?><pub-id pub-id-type="pmid">33007912</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Hu</surname><given-names>FB</given-names></string-name>, <string-name><surname>Manson</surname><given-names>JE</given-names></string-name></person-group>. <article-title>Marine omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials involving 127 477 participants</article-title>. <source>J Am Heart Assoc</source>. <year>2019</year>;<volume>8</volume>(<issue>19</issue>):<elocation-id>e013543</elocation-id>. doi:<pub-id pub-id-type="doi">10.1161/JAHA.119.013543</pub-id><?supplied-pmid 31567003?><pub-id pub-id-type="pmid">31567003</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Afilalo</surname><given-names>J</given-names></string-name>, <string-name><surname>Alexander</surname><given-names>KP</given-names></string-name>, <string-name><surname>Mack</surname><given-names>MJ</given-names></string-name>, <etal/></person-group>. <article-title>Frailty assessment in the cardiovascular care of older adults</article-title>. <source>J Am Coll Cardiol</source>. <year>2014</year>;<volume>63</volume>(<issue>8</issue>):<fpage>747</fpage>-<lpage>762</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jacc.2013.09.070</pub-id><?supplied-pmid 24291279?><pub-id pub-id-type="pmid">24291279</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Dupont</surname><given-names>J</given-names></string-name>, <string-name><surname>Dedeyne</surname><given-names>L</given-names></string-name>, <string-name><surname>Dalle</surname><given-names>S</given-names></string-name>, <string-name><surname>Koppo</surname><given-names>K</given-names></string-name>, <string-name><surname>Gielen</surname><given-names>E</given-names></string-name></person-group>. <article-title>The role of omega-3 in the prevention and treatment of sarcopenia</article-title>. <source>Aging Clin Exp Res</source>. <year>2019</year>;<volume>31</volume>(<issue>6</issue>):<fpage>825</fpage>-<lpage>836</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40520-019-01146-1</pub-id><?supplied-pmid 30784011?><pub-id pub-id-type="pmid">30784011</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Schulz</surname><given-names>KF</given-names></string-name>, <string-name><surname>Altman</surname><given-names>DG</given-names></string-name>, <string-name><surname>Moher</surname><given-names>D</given-names></string-name>; <collab>CONSORT Group</collab></person-group>. <article-title>CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials</article-title>. <source>Ann Intern Med</source>. <year>2010</year>;<volume>152</volume>(<issue>11</issue>):<fpage>726</fpage>-<lpage>732</lpage>. doi:<pub-id pub-id-type="doi">10.7326/0003-4819-152-11-201006010-00232</pub-id><?supplied-pmid 20335313?><pub-id pub-id-type="pmid">20335313</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hoogendijk</surname><given-names>EO</given-names></string-name>, <string-name><surname>Afilalo</surname><given-names>J</given-names></string-name>, <string-name><surname>Ensrud</surname><given-names>KE</given-names></string-name>, <string-name><surname>Kowal</surname><given-names>P</given-names></string-name>, <string-name><surname>Onder</surname><given-names>G</given-names></string-name>, <string-name><surname>Fried</surname><given-names>LP</given-names></string-name></person-group>. <article-title>Frailty: implications for clinical practice and public health</article-title>. <source>Lancet</source>. <year>2019</year>;<volume>394</volume>(<issue>10206</issue>):<fpage>1365</fpage>-<lpage>1375</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(19)31786-6</pub-id><?supplied-pmid 31609228?><pub-id pub-id-type="pmid">31609228</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Mitnitski</surname><given-names>AB</given-names></string-name>, <string-name><surname>Mogilner</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Rockwood</surname><given-names>K</given-names></string-name></person-group>. <article-title>Accumulation of deficits as a proxy measure of aging</article-title>. <source>ScientificWorldJournal</source>. <year>2001</year>;<volume>1</volume>:<fpage>323</fpage>-<lpage>336</lpage>. doi:<pub-id pub-id-type="doi">10.1100/tsw.2001.58</pub-id><?supplied-pmid 12806071?><pub-id pub-id-type="pmid">12806071</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Searle</surname><given-names>SD</given-names></string-name>, <string-name><surname>Mitnitski</surname><given-names>A</given-names></string-name>, <string-name><surname>Gahbauer</surname><given-names>EA</given-names></string-name>, <string-name><surname>Gill</surname><given-names>TM</given-names></string-name>, <string-name><surname>Rockwood</surname><given-names>K</given-names></string-name></person-group>. <article-title>A standard procedure for creating a frailty index</article-title>. <source>BMC Geriatr</source>. <year>2008</year>;<volume>8</volume>:<fpage>24</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1471-2318-8-24</pub-id><?supplied-pmid 18826625?><pub-id pub-id-type="pmid">18826625</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Orkaby</surname><given-names>AR</given-names></string-name>, <string-name><surname>Lunetta</surname><given-names>KL</given-names></string-name>, <string-name><surname>Sun</surname><given-names>FJ</given-names></string-name>, <etal/></person-group>. <article-title>Cross-sectional association of frailty and arterial stiffness in community-dwelling older adults: the Framingham Heart Study</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2019</year>;<volume>74</volume>(<issue>3</issue>):<fpage>373</fpage>-<lpage>379</lpage>. doi:<pub-id pub-id-type="doi">10.1093/gerona/gly134</pub-id><?supplied-pmid 29917058?><pub-id pub-id-type="pmid">29917058</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Orkaby</surname><given-names>AR</given-names></string-name>, <string-name><surname>Nussbaum</surname><given-names>L</given-names></string-name>, <string-name><surname>Ho</surname><given-names>YL</given-names></string-name>, <etal/></person-group>. <article-title>The burden of frailty among US veterans and its association with mortality, 2002-2012</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2019</year>;<volume>74</volume>(<issue>8</issue>):<fpage>1257</fpage>-<lpage>1264</lpage>. doi:<pub-id pub-id-type="doi">10.1093/gerona/gly232</pub-id><?supplied-pmid 30307533?><pub-id pub-id-type="pmid">30307533</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Blodgett</surname><given-names>J</given-names></string-name>, <string-name><surname>Theou</surname><given-names>O</given-names></string-name>, <string-name><surname>Kirkland</surname><given-names>S</given-names></string-name>, <string-name><surname>Andreou</surname><given-names>P</given-names></string-name>, <string-name><surname>Rockwood</surname><given-names>K</given-names></string-name></person-group>. <article-title>Frailty in NHANES: comparing the frailty index and phenotype</article-title>. <source>Arch Gerontol Geriatr</source>. <year>2015</year>;<volume>60</volume>(<issue>3</issue>):<fpage>464</fpage>-<lpage>470</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.archger.2015.01.016</pub-id><?supplied-pmid 25697060?><pub-id pub-id-type="pmid">25697060</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Clegg</surname><given-names>A</given-names></string-name>, <string-name><surname>Bates</surname><given-names>C</given-names></string-name>, <string-name><surname>Young</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Development and validation of an electronic frailty index using routine primary care electronic health record data</article-title>. <source>Age Ageing</source>. <year>2016</year>;<volume>45</volume>(<issue>3</issue>):<fpage>353</fpage>-<lpage>360</lpage>. doi:<pub-id pub-id-type="doi">10.1093/ageing/afw039</pub-id><?supplied-pmid 26944937?><pub-id pub-id-type="pmid">26944937</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ambagtsheer</surname><given-names>RC</given-names></string-name>, <string-name><surname>Beilby</surname><given-names>J</given-names></string-name>, <string-name><surname>Dabravolskaj</surname><given-names>J</given-names></string-name>, <string-name><surname>Abbasi</surname><given-names>M</given-names></string-name>, <string-name><surname>Archibald</surname><given-names>MM</given-names></string-name>, <string-name><surname>Dent</surname><given-names>E</given-names></string-name></person-group>. <article-title>Application of an electronic Frailty Index in Australian primary care: data quality and feasibility assessment</article-title>. <source>Aging Clin Exp Res</source>. 2019;31(5):653-660. doi:<pub-id pub-id-type="doi">10.1007/s40520-018-1023-9</pub-id><?supplied-pmid 30132204?><pub-id pub-id-type="pmid">30132204</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Pajewski</surname><given-names>NM</given-names></string-name>, <string-name><surname>Williamson</surname><given-names>JD</given-names></string-name>, <string-name><surname>Applegate</surname><given-names>WB</given-names></string-name>, <etal/>; <collab>SPRINT Study Research Group</collab></person-group>. <article-title>Characterizing frailty status in the Systolic Blood Pressure Intervention Trial</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2016</year>;<volume>71</volume>(<issue>5</issue>):<fpage>649</fpage>-<lpage>655</lpage>. doi:<pub-id pub-id-type="doi">10.1093/gerona/glv228</pub-id><?supplied-pmid 26755682?><pub-id pub-id-type="pmid">26755682</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Orkaby</surname><given-names>AR</given-names></string-name>, <string-name><surname>Hshieh</surname><given-names>TT</given-names></string-name>, <string-name><surname>Gaziano</surname><given-names>JM</given-names></string-name>, <string-name><surname>Djousse</surname><given-names>L</given-names></string-name>, <string-name><surname>Driver</surname><given-names>JA</given-names></string-name></person-group>. <article-title>Comparison of two frailty indices in the physicians’ health study</article-title>. <source>Arch Gerontol Geriatr</source>. <year>2017</year>;<volume>71</volume>:<fpage>21</fpage>-<lpage>27</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.archger.2017.02.009</pub-id><?supplied-pmid 28242579?><pub-id pub-id-type="pmid">28242579</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Warwick</surname><given-names>J</given-names></string-name>, <string-name><surname>Falaschetti</surname><given-names>E</given-names></string-name>, <string-name><surname>Rockwood</surname><given-names>K</given-names></string-name>, <etal/></person-group>. <article-title>No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the Hypertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over</article-title>. <source>BMC Med</source>. <year>2015</year>;<volume>13</volume>:<fpage>78</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12916-015-0328-1</pub-id><?supplied-pmid 25880068?><pub-id pub-id-type="pmid">25880068</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Mitnitski</surname><given-names>A</given-names></string-name>, <string-name><surname>Song</surname><given-names>X</given-names></string-name>, <string-name><surname>Skoog</surname><given-names>I</given-names></string-name>, <etal/></person-group>. <article-title>Relative fitness and frailty of elderly men and women in developed countries and their relationship with mortality</article-title>. <source>J Am Geriatr Soc</source>. <year>2005</year>;<volume>53</volume>(<issue>12</issue>):<fpage>2184</fpage>-<lpage>2189</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1532-5415.2005.00506.x</pub-id><?supplied-pmid 16398907?><pub-id pub-id-type="pmid">16398907</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Jang</surname><given-names>IY</given-names></string-name>, <string-name><surname>Jung</surname><given-names>H-W</given-names></string-name>, <string-name><surname>Lee</surname><given-names>HY</given-names></string-name>, <string-name><surname>Park</surname><given-names>H</given-names></string-name>, <string-name><surname>Lee</surname><given-names>E</given-names></string-name>, <string-name><surname>Kim</surname><given-names>DH</given-names></string-name></person-group>. <article-title>Evaluation of clinically meaningful changes in measures of frailty</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2020</year>;<volume>75</volume>(<issue>6</issue>):<fpage>1143</fpage>-<lpage>1147</lpage>. doi:<pub-id pub-id-type="doi">10.1093/gerona/glaa003</pub-id><?supplied-pmid 32145016?><pub-id pub-id-type="pmid">32145016</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Simpson</surname><given-names>FR</given-names></string-name>, <string-name><surname>Pajewski</surname><given-names>NM</given-names></string-name>, <string-name><surname>Nicklas</surname><given-names>B</given-names></string-name>, <etal/>; <collab>Indices for Accelerated Aging in Obesity and Diabetes Ancillary Study of the Action for Health in Diabetes (Look AHEAD) Trial</collab></person-group>. <article-title>Impact of Multidomain Lifestyle Intervention on Frailty Through the Lens of Deficit Accumulation in Adults with Type 2 Diabetes Mellitus</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2020</year>;<volume>75</volume>(<issue>10</issue>):<fpage>1921</fpage>-<lpage>1927</lpage>. doi:<pub-id pub-id-type="doi">10.1093/gerona/glz197</pub-id><?supplied-pmid 31559418?><pub-id pub-id-type="pmid">31559418</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Mitnitski</surname><given-names>AB</given-names></string-name>, <string-name><surname>Graham</surname><given-names>JE</given-names></string-name>, <string-name><surname>Mogilner</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Rockwood</surname><given-names>K</given-names></string-name></person-group>. <article-title>Frailty, fitness and late-life mortality in relation to chronological and biological age</article-title>. <source>BMC Geriatr</source>. <year>2002</year>;<volume>2</volume>:<fpage>1</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1471-2318-2-1</pub-id><?supplied-pmid 11897015?><pub-id pub-id-type="pmid">11897015</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>López-Otín</surname><given-names>C</given-names></string-name>, <string-name><surname>Blasco</surname><given-names>MA</given-names></string-name>, <string-name><surname>Partridge</surname><given-names>L</given-names></string-name>, <string-name><surname>Serrano</surname><given-names>M</given-names></string-name>, <string-name><surname>Kroemer</surname><given-names>G</given-names></string-name></person-group>. <article-title>The hallmarks of aging</article-title>. <source>Cell</source>. <year>2013</year>;<volume>153</volume>(<issue>6</issue>):<fpage>1194</fpage>-<lpage>1217</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2013.05.039</pub-id><?supplied-pmid 23746838?><pub-id pub-id-type="pmid">23746838</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Walker</surname><given-names>KA</given-names></string-name>, <string-name><surname>Basisty</surname><given-names>N</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>DM</given-names><suffix>III</suffix></string-name>, <string-name><surname>Ferrucci</surname><given-names>L</given-names></string-name></person-group>. <article-title>Connecting aging biology and inflammation in the omics era</article-title>. <source>J Clin Invest</source>. <year>2022</year>;<volume>132</volume>(<issue>14</issue>):<elocation-id>e158448</elocation-id>. doi:<pub-id pub-id-type="doi">10.1172/JCI158448</pub-id><?supplied-pmid 35838044?><pub-id pub-id-type="pmid">35838044</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Dodds</surname><given-names>R</given-names></string-name>, <string-name><surname>Sayer</surname><given-names>AA</given-names></string-name></person-group>. <article-title>Sarcopenia and frailty: new challenges for clinical practice</article-title>. <source>Clin Med (Lond)</source>. <year>2016</year>;<volume>16</volume>(<issue>5</issue>):<fpage>455</fpage>-<lpage>458</lpage>. doi:<pub-id pub-id-type="doi">10.7861/clinmedicine.16-5-455</pub-id><?supplied-pmid 27697810?><pub-id pub-id-type="pmid">27697810</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Lopez-Garcia</surname><given-names>E</given-names></string-name>, <string-name><surname>Hagan</surname><given-names>KA</given-names></string-name>, <string-name><surname>Fung</surname><given-names>TT</given-names></string-name>, <string-name><surname>Hu</surname><given-names>FB</given-names></string-name>, <string-name><surname>Rodríguez-Artalejo</surname><given-names>F</given-names></string-name></person-group>. <article-title>Mediterranean diet and risk of frailty syndrome among women with type 2 diabetes</article-title>. <source>Am J Clin Nutr</source>. <year>2018</year>;<volume>107</volume>(<issue>5</issue>):<fpage>763</fpage>-<lpage>771</lpage>. doi:<pub-id pub-id-type="doi">10.1093/ajcn/nqy026</pub-id><?supplied-pmid 29722845?><pub-id pub-id-type="pmid">29722845</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ward</surname><given-names>RE</given-names></string-name>, <string-name><surname>Orkaby</surname><given-names>AR</given-names></string-name>, <string-name><surname>Chen</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Association between diet quality and frailty prevalence in the Physicians’ Health Study</article-title>. <source>J Am Geriatr Soc</source>. <year>2020</year>;<volume>68</volume>(<issue>4</issue>):<fpage>770</fpage>-<lpage>776</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jgs.16286</pub-id><?supplied-pmid 31840808?><pub-id pub-id-type="pmid">31840808</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Bischoff-Ferrari</surname><given-names>HA</given-names></string-name>, <string-name><surname>Vellas</surname><given-names>B</given-names></string-name>, <string-name><surname>Rizzoli</surname><given-names>R</given-names></string-name>, <etal/>; <collab>DO-HEALTH Research Group</collab></person-group>. <article-title>Effect of vitamin D supplementation, omega-3 fatty acid supplementation, or a strength-training exercise program on clinical outcomes in older adults: the DO-HEALTH randomized clinical trial</article-title>. <source>JAMA</source>. <year>2020</year>;<volume>324</volume>(<issue>18</issue>):<fpage>1855</fpage>-<lpage>1868</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2020.16909</pub-id><?supplied-pmid 33170239?><pub-id pub-id-type="pmid">33170239</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Abellan van Kan</surname><given-names>G</given-names></string-name>, <string-name><surname>Rolland</surname><given-names>Y</given-names></string-name>, <string-name><surname>Bergman</surname><given-names>H</given-names></string-name>, <string-name><surname>Morley</surname><given-names>JE</given-names></string-name>, <string-name><surname>Kritchevsky</surname><given-names>SB</given-names></string-name>, <string-name><surname>Vellas</surname><given-names>B</given-names></string-name></person-group>. <article-title>The I.A.N.A Task Force on frailty assessment of older people in clinical practice</article-title>. <source>J Nutr Health Aging</source>. <year>2008</year>;<volume>12</volume>(<issue>1</issue>):<fpage>29</fpage>-<lpage>37</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF02982161</pub-id><?supplied-pmid 18165842?><pub-id pub-id-type="pmid">18165842</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Beaudart</surname><given-names>C</given-names></string-name>, <string-name><surname>Buckinx</surname><given-names>F</given-names></string-name>, <string-name><surname>Rabenda</surname><given-names>V</given-names></string-name>, <etal/></person-group>. <article-title>The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2014</year>;<volume>99</volume>(<issue>11</issue>):<fpage>4336</fpage>-<lpage>4345</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jc.2014-1742</pub-id><?supplied-pmid 25033068?><pub-id pub-id-type="pmid">25033068</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kahwati</surname><given-names>LC</given-names></string-name>, <string-name><surname>Weber</surname><given-names>RP</given-names></string-name>, <string-name><surname>Pan</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults: evidence report and systematic review for the US Preventive Services Task Force</article-title>. <source>JAMA</source>. <year>2018</year>;<volume>319</volume>(<issue>15</issue>):<fpage>1600</fpage>-<lpage>1612</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2017.21640</pub-id><?supplied-pmid 29677308?><pub-id pub-id-type="pmid">29677308</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Khaw</surname><given-names>KT</given-names></string-name>, <string-name><surname>Stewart</surname><given-names>AW</given-names></string-name>, <string-name><surname>Waayer</surname><given-names>D</given-names></string-name>, <etal/></person-group>. <article-title>Effect of monthly high-dose vitamin D supplementation on falls and non-vertebral fractures: secondary and post-hoc outcomes from the randomised, double-blind, placebo-controlled ViDA trial</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2017</year>;<volume>5</volume>(<issue>6</issue>):<fpage>438</fpage>-<lpage>447</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2213-8587(17)30103-1</pub-id><?supplied-pmid 28461159?><pub-id pub-id-type="pmid">28461159</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>LeBoff</surname><given-names>MS</given-names></string-name>, <string-name><surname>Murata</surname><given-names>EM</given-names></string-name>, <string-name><surname>Cook</surname><given-names>NR</given-names></string-name>, <etal/></person-group>. <article-title>Vitamin D and Omega-3 Trial (VITAL): effects of vitamin D supplements on risk of falls in the US population</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2020</year>;<volume>105</volume>(<issue>9</issue>):<fpage>2929</fpage>-<lpage>2938</lpage>. doi:<pub-id pub-id-type="doi">10.1210/clinem/dgaa311</pub-id><?supplied-pmid 32492153?><pub-id pub-id-type="pmid">32492153</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Chong</surname><given-names>ZZ</given-names></string-name>, <string-name><surname>Shang</surname><given-names>YC</given-names></string-name>, <string-name><surname>Maiese</surname><given-names>K</given-names></string-name></person-group>. <article-title>Cardiovascular disease and mTOR signaling</article-title>. <source>Trends Cardiovasc Med</source>. <year>2011</year>;<volume>21</volume>(<issue>5</issue>):<fpage>151</fpage>-<lpage>155</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tcm.2012.04.005</pub-id><?supplied-pmid 22732551?><pub-id pub-id-type="pmid">22732551</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r42">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>León-Muñoz</surname><given-names>LM</given-names></string-name>, <string-name><surname>Guallar-Castillón</surname><given-names>P</given-names></string-name>, <string-name><surname>López-García</surname><given-names>E</given-names></string-name>, <string-name><surname>Rodríguez-Artalejo</surname><given-names>F</given-names></string-name></person-group>. <article-title>Mediterranean diet and risk of frailty in community-dwelling older adults</article-title>. <source>J Am Med Dir Assoc</source>. <year>2014</year>;<volume>15</volume>(<issue>12</issue>):<fpage>899</fpage>-<lpage>903</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jamda.2014.06.013</pub-id><?supplied-pmid 25127502?><pub-id pub-id-type="pmid">25127502</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r43">
                <label>43</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Joyce</surname><given-names>E</given-names></string-name></person-group>. <article-title>Frailty and cardiovascular disease: a two-way street?</article-title><source>Cleve Clin J Med</source>. <year>2018</year>;<volume>85</volume>(<issue>1</issue>):<fpage>65</fpage>-<lpage>68</lpage>. doi:<pub-id pub-id-type="doi">10.3949/ccjm.85a.17075</pub-id><?supplied-pmid 29328894?><pub-id pub-id-type="pmid">29328894</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r44">
                <label>44</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Blodgett</surname><given-names>JM</given-names></string-name>, <string-name><surname>Rockwood</surname><given-names>K</given-names></string-name>, <string-name><surname>Theou</surname><given-names>O</given-names></string-name></person-group>. <article-title>Changes in the severity and lethality of age-related health deficit accumulation in the USA between 1999 and 2018: a population-based cohort study</article-title>. <source>Lancet Healthy Longev</source>. <year>2021</year>;<volume>2</volume>(<issue>2</issue>):<fpage>e96</fpage>-<lpage>e104</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2666-7568(20)30059-3</pub-id><pub-id pub-id-type="pmid">36098163</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r45">
                <label>45</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Theou</surname><given-names>O</given-names></string-name>, <string-name><surname>Brothers</surname><given-names>TD</given-names></string-name>, <string-name><surname>Mitnitski</surname><given-names>A</given-names></string-name>, <string-name><surname>Rockwood</surname><given-names>K</given-names></string-name></person-group>. <article-title>Operationalization of frailty using eight commonly used scales and comparison of their ability to predict all-cause mortality</article-title>. <source>J Am Geriatr Soc</source>. <year>2013</year>;<volume>61</volume>(<issue>9</issue>):<fpage>1537</fpage>-<lpage>1551</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jgs.12420</pub-id><?supplied-pmid 24028357?><pub-id pub-id-type="pmid">24028357</pub-id></mixed-citation>
              </ref>
              <ref id="zoi220884r46">
                <label>46</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Espinoza</surname><given-names>SE</given-names></string-name></person-group>. <article-title>The association of prior intensive lifestyle intervention and diabetes support and education with frailty prevalence at long-term follow-up in the Action for Health in Diabetes Extension Study</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2021</year>;<elocation-id>glab312</elocation-id>. doi:<pub-id pub-id-type="doi">10.1093/gerona/glab312</pub-id><?supplied-pmid 34637524?><pub-id pub-id-type="pmid">34637524</pub-id></mixed-citation>
              </ref>
            </ref-list>
            <notes notes-type="supplementary-material" id="note-ZOI220884-1">
              <supplementary-material id="note-ZOI220884-1-s" position="float" content-type="local-data">
                <label>Supplement 1.</label>
                <caption>
                  <p>
Trial Protocol
</p>
                </caption>
                <media xlink:href="jamanetwopen-e2231206-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 2.</label>
                <caption>
                  <p>
Ancillary Trial Protocol
</p>
                </caption>
                <media xlink:href="jamanetwopen-e2231206-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 3.</label>
                <caption>
                  <p><bold>eTable 1.</bold> Cumulative Deficit Frailty Index Components for the VITAL Trial</p>
                  <p><bold>eTable 2.</bold> Fried Physical Phenotype of Frailty in VITAL Subcohort (n=1054)</p>
                  <p><bold>eTable 3.</bold> Baseline Characteristics of the VITAL Trial (n=25 057) According to Frailty Status</p>
                  <p><bold>eTable 4. </bold>Adjusted Means at Baseline and Mean Change (95% CI) in Frailty level at Each Year Since Randomization Compared to Baseline, According to Vitamin D vs placebo and Omega-3 vs Placebo Groups</p>
                  <p><bold>eTable 5. </bold>Baseline Characteristics of 1054 Participants in the VITAL Trial in Person Subgroup</p>
                  <p><bold>eTable 6A. </bold>Adjusted Means at Baseline and Mean Change (95% CI) in Fried Frailty Level at Each Year Since Randomization Compared to Baseline, According to Vitamin D and Placebo Groups</p>
                  <p><bold>eTable 6B. </bold>Adjusted Means at Baseline and Mean Change (95% CI) in Fried Frailty Level at Each Year Since Randomization Compared to Baseline, According to n-3 and Placebo Groups</p>
                  <p><bold>eFigure 1. </bold>Distribution of Frailty Index at Baseline</p>
                  <p><bold>eFigure 2. </bold>Distribution of Frailty Index at Baseline According to Randomization Group</p>
                  <p><bold>eFigure 3.</bold> Validation of the FI: Association Between FI Level and Mortality</p>
                  <p><bold>eFigure 4A.</bold> Effect of Vitamin D<sub>3</sub> on Incident Frailty Over Time</p>
                  <p><bold>eFigure 4B.</bold> Effect of Omega-3 on Incident Frailty Over Time</p>
                  <p><bold>eFigure 5.</bold> Vitamin D<sub>3</sub> Supplementation and Frailty Subgroups</p>
                  <p><bold>eFigure 6.</bold> Omega-3 Supplementation and Frailty Subgroups</p>
                  <p><bold>eFigure 7.</bold> Effect of Vitamin D<sub>3</sub> on Incident Fried Frailty Over Time</p>
                  <p><bold>eFigure 8.</bold> Effect of Omega-3 on Incident Fried Frailty Over Time</p>
                  <p>
eReferences
</p>
                </caption>
                <media xlink:href="jamanetwopen-e2231206-s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 4.</label>
                <caption>
                  <p>
Data Sharing Statement
</p>
                </caption>
                <media xlink:href="jamanetwopen-e2231206-s004.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </notes>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
